International Journal of Basic & Clinical Pharmacology (IJBCP) is an open access, international, peer-reviewed journal. The journal's full text is available online at The journal allows free access to its contents. IJBCP publishes important advances in pharmacology that include basic and clinical studies of all aspects of pharmacology in human, animal and cell-line studies. The journal also accepts articles on traditional medicine. The journal has a broad coverage of relevant topics across pharmacology including ethics, research methodology, data management, drug utilisation, regulatory, teaching and biostatistics. IJBCP is one of the fastest communication journals and articles are published online within short time after acceptance of manuscripts. The types of articles accepted include original research articles, review articles, case reports, conference abstracts, general articles in the field of basic and clinical pharmacology, new drug updates and letters to the editor. It is published every two months and available in print and online version. IJBCP complies with the uniform requirements for manuscripts submitted to biomedical journals, issued by the International Committee for Medical Journal Editors.
From 2-7 July 2023, the global pharmacology and therapeutics community will unite in Glasgow, Scotland for six days of cutting-edge science and unmissable career opportunity. View our extensive programme and register now.
It was an honor to receive this award and be granted the opportunity to learn at the World Congress of Pharmacology. As a pharmacist, I was excited to see many clinicians representing healthcare institutions around the world at this meeting. My favorite sessions provided new insight into the perspective of clinical pharmacists from other countries and the differences in our scopes of practice. I learned, for instance, that hospitals in Europe may often only employ a few pharmacists per institution, whereas many hospitals in the U.S. have pharmacists working in each unit. I particularly enjoyed presentations regarding issues in pediatric drug development, including pharmacogenomics, pharmacometrics, and formulations. The unique setting of this meeting encouraged discussion of how regulatory changes were occurring worldwide to address the growing demand for safety and efficacy data in pediatric patients and other special populations. This experience will benefit me in my career as a scientist as I continue to work with a global community of clinicians.
Basic & Clinical Pharmacology & Toxicology is the journal of the Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society) and publishes original scientific research in all fields of toxicology, basic and clinical pharmacology.
Organized to reflect the syllabi in many pharmacology courses and in integrated curricula, Basic & Clinical Pharmacology, Fourteenth Edition covers the important concepts students need to know about the science of pharmacology and its application to clinical practice. Selection of the subject matter and order of its presentation are based on the authors' many years' experience in teaching this material to thousands of medical, pharmacy, dental, podiatry, nursing, and other health science students.
To be as clinically relevant as possible, the book includes sections that specifically address the clinical choice and use of drugs in patients and the monitoring of their effects, and case studies that introduce clinical problems in many chapters. Presented in full color and enhanced by more than three hundred illustrations (many new to this edition), Basic & Clinical Pharmacology features numerous summary tables and diagrams that encapsulate important information.
- Student-acclaimed summary tables conclude each chapter- Everything students need to know about the science of pharmacology and its application to clinical practice - Strong emphasis on drug groups and prototypes - NEW! 100 new drug tables- Includes 330 full-color illustrations, case studies, and chapter-ending summary tables - Organized to reflect the syllabi of pharmacology courses - Descriptions of important new drugs
Organized to reflect the course sequence in many pharmacology courses and in integrated curricula, the guide covers the important concepts students need to know about the science of pharmacology and its application to clinical practice. This edition has been extensively updated to provide expanded coverage of transporters, pharmacogenomics, and new drugs
Clinical pharmacology offers a unique opportunity to combine the basic and clinical research efforts of multiple departments and centers across the medical school to focus on the development and clinical use of drugs. A major strength of clinical pharmacology is a broad research effort encompassing many different therapeutic areas, including pharmacometrics and quantitative clinical pharmacology expertise in pediatric and adult antivirals, oncology, neuropharmacology, and other disease states.
Clinical pharmacology encompasses all aspects of the relationship between drugs and humans. For healthcare professionals, clinical pharmacology is important because it is the scientific discipline that underpins the rational prescribing of medicines to alleviate symptoms, treat illness and prevent future disease. Medicines contain drugs (the specific chemical substances with pharmacological effects), either alone or in combination, in a formulation mixed with other ingredients. The beneficial effects of medicines must be weighed against potential adverse drug reactions and interactions, often caused by injudicious prescribing decisions and by prescribing errors, and their cost.
The Clinical Division of IUPHAR (International Union of Basic and Clinical Pharmacology) has produced a comprehensive model geriatric pharmacology curriculum for medical education that is applicable internationally.
The suggested curriculum identifies eight key areas where the effects of ageing have impact clinical pharmacology, and which should be considered independently of (and/or in addtion to) general clinical pharmacology:
Link to an article published in the journal Pharmacological Research in 2019. In this paper, Kashyap et al. provide a comprehensive teaching curriculum that covers the field of geriatric clinical pharmacology, a topic that is often taught fleetingly in medical school programmes.
The Pharmacology Education Project (PEP) is being developed by The International Union of Basic and Clinical Pharmacology (IUPHAR), with support from sponsors, as a service to the international pharmacology community.
This international congress fosters basic, clinical (therapeutic) and translational fields of pharmacological sciences. It creates a forum to discuss the latest developments in pharmacological sciences, to build collaboration networks, and to get an opportunity to listen to and interact with the world's leading pharmacologists.
This eLearning course reviews the principles of safety sciences including toxicology, clinical pharmacology, pharmacogenomics, and pharmacoepidemiology to enable you to analyze potential safety issues, and to better understand the patient population and its experience with the drug. The course will walk learners through activities and associated competencies needed to advance a drug candidate from an idea in a lab to a treatment ready to be studied in humans. Keep in mind that the application of these sciences to safety and pharmacovigilance change as the environment, regulations, and guidance for drug development continue to evolve.
The overall goals of the program are to integrate training in methodologies, concepts, and approaches of basic and clinical pharmacology across the developmental continuum and in hypothesis-driven basic and clinical research. The program seeks to produce investigators who can establish competitive basic, translational, and/or clinical research programs, and bridge the gap between the laboratory and the patient, as well as between children and adults. Programs are individually tailored to the trainee's professional interests and goals. The expected duration of training is two or three years.
Journal Impact Factor: 10.2*e-ISSN: 0976-0113Articles Published in PubMed Central: 195*Journal of Basic and Clinical Pharmacy (JBCP) is an international, peer reviewed journal that publishes original scientific research that is relevant to a broad audience of pharmacy researchers and practicing pharmacy professionals. Journal of Basic and Clinical Pharmacy welcomes original research, short communications, comprehensive reviews, case reports that furthers knowledge in the areas of basic and clinical pharmacy.
Metabotropic glutamate (mGlu) receptors respond to glutamate, the major excitatory neurotransmitter in the mammalian brain, mediating a modulatory role that is critical for higher-order brain functions such as learning and memory. Since the first mGlu receptor was cloned in 1992, eight subtypes have been identified along with many isoforms and splice variants. The mGlu receptors are transmembrane-spanning proteins belonging to the class C G protein-coupled receptor family and represent attractive targets for a multitude of central nervous system disorders. Concerted drug discovery efforts over the past three decades have yielded a wealth of pharmacological tools including subtype-selective agents that competitively block or mimic the actions of glutamate or act allosterically via distinct sites to enhance or inhibit receptor activity. Herein, we review the physiologic and pathophysiological roles for individual mGlu receptor subtypes including the pleiotropic nature of intracellular signal transduction arising from each. We provide a comprehensive analysis of the in vitro and in vivo pharmacological properties of prototypical and commercially available orthosteric agonists and antagonists as well as allosteric modulators, including ligands that have entered clinical trials. Finally, we highlight emerging areas of research that hold promise to facilitate rational design of highly selective mGlu receptor-targeting therapeutics in the future. SIGNIFICANCE STATEMENT: The metabotropic glutamate receptors are attractive therapeutic targets for a range of psychiatric and neurological disorders. Over the past three decades, intense discovery efforts have yielded diverse pharmacological tools acting either competitively or allosterically, which have enabled dissection of fundamental biological process modulated by metabotropic glutamate receptors and established proof of concept for many therapeutic indications. We review metabotropic glutamate receptor molecular pharmacology and highlight emerging areas that are offering new avenues to selectively modulate neurotransmission. 59ce067264